Palisade Bio (PALI) Competitors $0.79 +0.01 (+1.51%) Closing price 03:59 PM EasternExtended Trading$0.78 -0.01 (-1.56%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. SYBX, QNTM, ABP, LSB, ORGS, TXMD, BGXX, AFMD, NERV, and RLYBShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Synlogic (SYBX), Quantum Biopharma (QNTM), Abpro (ABP), Lakeshore Biopharma (LSB), Orgenesis (ORGS), TherapeuticsMD (TXMD), Bright Green (BGXX), Affimed (AFMD), Minerva Neurosciences (NERV), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Synlogic Quantum Biopharma Abpro Lakeshore Biopharma Orgenesis TherapeuticsMD Bright Green Affimed Minerva Neurosciences Rallybio Palisade Bio (NASDAQ:PALI) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends. Which has preferable valuation and earnings, PALI or SYBX? Palisade Bio has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K13.94-$12.30M-$10.92-0.07Synlogic$8K1,695.92-$57.28M-$2.51-0.46 Does the media prefer PALI or SYBX? In the previous week, Palisade Bio had 1 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.44 beat Palisade Bio's score of 0.96 indicating that Synlogic is being referred to more favorably in the news media. Company Overall Sentiment Palisade Bio Positive Synlogic Positive Do institutionals & insiders hold more shares of PALI or SYBX? 11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 3.3% of Palisade Bio shares are held by insiders. Comparatively, 3.0% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, PALI or SYBX? Palisade Bio has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Does the MarketBeat Community prefer PALI or SYBX? Synlogic received 321 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote. CompanyUnderperformOutperformPalisade BioOutperform Votes1050.00% Underperform Votes1050.00% SynlogicOutperform Votes33169.54% Underperform Votes14530.46% Do analysts prefer PALI or SYBX? Palisade Bio presently has a consensus price target of $23.00, suggesting a potential upside of 2,802.57%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Palisade Bio is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PALI or SYBX more profitable? Palisade Bio's return on equity of -148.51% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -148.51% -115.16% Synlogic N/A -207.84%-114.81% SummaryPalisade Bio beats Synlogic on 10 of the 17 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48M$2.97B$5.56B$8.04BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-0.0630.5222.6818.83Price / Sales13.94494.70404.28106.72Price / CashN/A168.6838.1834.62Price / Book0.043.216.794.33Net Income-$12.30M-$72.35M$3.22B$247.97M7 Day Performance8.85%3.75%2.44%2.71%1 Month Performance18.69%7.34%3.78%3.37%1 Year Performance-89.13%-22.52%17.05%5.80% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio3.205 of 5 stars$0.79+1.5%$23.00+2,802.6%-89.0%$3.48M$250,000.00-0.0610News CoverageGap UpSYBXSynlogic2.4883 of 5 stars$1.06+0.0%N/A-39.2%$12.40M$8,000.00-0.2580Short Interest ↓Positive NewsGap UpQNTMQuantum BiopharmaN/A$6.24-1.0%N/AN/A$11.98MN/A-0.40N/AUpcoming EarningsPositive NewsABPAbproN/A$0.23-10.5%$4.00+1,631.6%N/A$11.97M$122,000.000.0015Gap UpHigh Trading VolumeLSBLakeshore Biopharma1.3979 of 5 stars$1.28-7.2%N/AN/A$11.91M$672.27M0.00773Short Interest ↓Gap UpORGSOrgenesisN/A$2.48+13.2%N/AN/A$11.90M$662,000.000.00150Gap UpTXMDTherapeuticsMD1.7736 of 5 stars$1.00-1.4%N/A-26.1%$11.53M$1.76M0.00420Upcoming EarningsAnalyst ForecastBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownAFMDAffimed3.5162 of 5 stars$0.70-4.0%$13.50+1,818.2%-79.4%$11.33M$877,000.000.00200NERVMinerva Neurosciences3.7991 of 5 stars$1.66+3.8%$5.00+201.2%-27.7%$11.19MN/A-3.779RLYBRallybio2.342 of 5 stars$0.27+6.0%$10.00+3,672.2%-84.1%$11.03M$636,000.00-0.1740Upcoming EarningsGap Up Related Companies and Tools Related Companies SYBX Alternatives QNTM Alternatives ABP Alternatives LSB Alternatives ORGS Alternatives TXMD Alternatives BGXX Alternatives AFMD Alternatives NERV Alternatives RLYB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PALI Stock Free PALI Stock Alerts